Table 3 Selected clinical studies on... | American Society of Hematology

Table 3

Selected clinical studies on treatment options with novel agents in patients with relapsed/refractory cHL after ASCT

Agent	No. of patients	Prior ASCT	Response, %	PFS	Reference
Brentuximab	102	102	ORR, 75	5.6 mo	28
			CR, 34
			PR, 41
Nivolumab	23	18	ORR, 87	24-wk 86%	29
			CR, 17
			PR, 70
Pembrolizumab	15	10	ORR, 53	NR	30
			CR, 20
			PR, 33
Lenalidomide	36	31	ORR, 19	6 mo	31
			CR, 3		58
			PR, 16		59
Rituximab	22	18	ORR, 22	7.8 mo	60
			CR, 4.5
			PR, 18
Everolimus	19	16	ORR, 47	7.2 mo	32
			CR, 5
			PR, 42
Vorinostat	25	11	ORR, 4	4.8 mo	61
			CR, 0
			PR, 4
Panobinostat	129	129	ORR, 27	6.1 mo	33
			CR, 4
			PR, 23

Agent	No. of patients	Prior ASCT	Response, %	PFS	Reference
Brentuximab	102	102	ORR, 75	5.6 mo	28
			CR, 34
			PR, 41
Nivolumab	23	18	ORR, 87	24-wk 86%	29
			CR, 17
			PR, 70
Pembrolizumab	15	10	ORR, 53	NR	30
			CR, 20
			PR, 33
Lenalidomide	36	31	ORR, 19	6 mo	31
			CR, 3		58
			PR, 16		59
Rituximab	22	18	ORR, 22	7.8 mo	60
			CR, 4.5
			PR, 18
Everolimus	19	16	ORR, 47	7.2 mo	32
			CR, 5
			PR, 42
Vorinostat	25	11	ORR, 4	4.8 mo	61
			CR, 0
			PR, 4
Panobinostat	129	129	ORR, 27	6.1 mo	33
			CR, 4
			PR, 23